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Randomized clinical trial of open-cell vs
closed-cell stents for carotid stenting and effects of
stent design on cerebral embolization
Carlos H. Timaran, MD,a,b Eric B. Rosero, MD,b Adriana Higuera, MD,b Adriana Ilarraza, BS,b
J. Gregory Modrall, MD,a,b and G. Patrick Clagett, MD,b Dallas, Tex
Objective: The effect of stent design on cerebral embolization has not been established. The purpose of this trial was to
contrast the incidence of subclinical cerebral embolization in high-risk patients undergoing carotid artery stenting (CAS)
with open-cell vs closed-cell stents.
Methods: During an 18-month period, 40 patients were randomized (1:1) to undergo CAS with open-cell (Acculink, n 
20) or closed-cell stents (Xact, n 20). A single filter device for embolic protection (Accunet filter) was used. Transcranial
Doppler (TCD)-detected microembolic signals (MES) during CAS and preprocedural and 24-hour postprocedural
diffusion-weighted magnetic resonance imaging (DW-MRI) were used to determine cerebral embolization. Univariate
and nonparametric analyses were used to assess associations between stent design and cerebral embolization.
Results:CASwas performed in 17 symptomatic patients (43%) and 23 asymptomatic patients (57%) with a similar number
of open-cell and closed-cell stents (9/8 and 11/12, respectively). The total and poststenting median ipsilateral MES
counts detected by TCD were 264 (interquartile range [IQR], 222-343) and 48 (IQR, 41-66) for open-cell stents and
339 (IQR, 163-408) and 53 (IQR, 23-88) for closed-cell stents, respectively (P > .56). New acute cerebral emboli
detected with DW-MRI occurred in 53% and 47% of patients undergoing CAS with open-cell and closed-cell stents,
respectively (P 1.0). The total and ipsilateral median numbers of DW-MRI lesions between groups were not statistically
significantly different (ie, 2 [IQR, 0-4] and 1 [IQR, 0-3] for open-cell stents and 1 [IQR, 0-3] and 1 [IQR, 0-2] for
closed cell-stents, respectively; P > .4). One asymptomatic patient undergoing CAS with an open-cell stent sustained a
minor stroke; the 30-day stroke-death rate in this series was 2.5%.
Conclusion: Cerebral embolization, as detected by TCD and DW-MRI, occurs with similar frequency after CAS with
open-cell and closed-cell stents. This randomized trial does not support the superiority of any stent design with respect
to cerebral embolization. (J Vasc Surg 2011;54:1310-6.)
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tCarotid interventions are effective measures in prevent-
ing stroke and death among patients with significant ca-
rotid stenosis.1-5 Although carotid endarterectomy (CEA)
has been the primary treatment option for carotid stenosis,
carotid artery stenting (CAS) is currently an alternative in
patients with a high risk for CEA.6,7 More recently, the
Carotid Revascularization Endarterectomy versus Stenting
Trial8,9 did not reveal any significant differences between
CAS and CEA among standard-risk patients based on a
composite primary endpoint of periprocedural stroke, myo-
cardial infarction, or death and ipsilateral stroke thereafter,
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1310lthough a higher risk of stroke with CAS and a higher risk
f myocardial infarction with CEA were observed during
he periprocedural period. Until the US Food and Drug
dministration approves an expanded indication for CAS
evices for standard-risk patients, CAS should be reserved
rimarily for high-risk patients.
Although several predictors of adverse outcomes after
AS have been identified, the effects of device characteris-
ics, including stent design, on neurologic adverse events
ave not been established. Recent observational retrospec-
ive studies suggest that the use of closed-cell stents (ie,
hose with smaller free cell area of aligned annular rings)
ay be associated with lower stroke and death rates after
AS compared with open-cell stents.10,11 Such beneficial
ffects, however, have not been proven in hypothesis-
riven prospective observational studies or randomized
rials. Moreover, a direct comparison between open-cell
nd closed-cell stents will be required to expand the results
f the Carotid Revascularization Endarterectomy versus
tenting Trial, in which only the Acculink open-cell stent
Abbott Vascular, Santa Clara, Calif) was used for CAS, to
he existing closed-cell stents.
Diffusion-weightedmagnetic resonance imaging (DW-
RI) and transcranial Doppler (TCD) are imaging tech-
iques frequently used to detect cerebral microemboliza-
ion during carotid interventions.12-18 Because adverse
eurologic events after CAS are rare events in high-volume
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Volume 54, Number 5 Timaran et al 1311practices, quantification of microembolization using DW-
MRI and TCD monitoring may be used as surrogate end-
points of cerebral embolization during CAS.16,18 The goal
of the proposed study was to contrast the relative efficacy of
closed-cell stents vs open-cell stents in preventing peripro-
cedural cerebral embolization in high-risk patients with
symptomatic and asymptomatic extracranial carotid steno-
sis undergoing CAS.
METHODS
During an 18-month period, 40 male patients at high
risk or with contraindications for CEA were enrolled and
randomized 1:1 to undergo CAS with open-cell or closed-
cell stents. Indications for CAS included moderate (50% or
greater) symptomatic carotid stenosis or severe (80% or
greater) asymptomatic carotid stenosis determined with
duplex ultrasound scan and confirmed during the proce-
dure with digital subtraction angiography. Measurements
of angiographic carotid stenosis (percentage by diameter)
were performed according to North American Symptom-
atic Carotid Endarterectomy methodology.2 This study
was reviewed and approved by the North Texas Veterans
Affairs Administration institutional review board.
After eligible patients agreed to participate in the study
and signed informed consent, patients were randomized to
an open-cell stent (Acculink carotid stent; Abbott Vascular,
Santa Clara, Calif) or a closed-cell stent (Xact carotid stent,
Abbott Vascular). Randomization was performed bymeans
of a randomization list (sealed envelopes) prepared in
blocks of four patients. Patients were evenly randomized to
one of two treatment arms with each treatment arm having
the probability of one-half (P .5). Patients were assigned
in equal proportions in a double-blind fashion (patient and
outcome assessors) to treatment with either the Acculink
open-cell stent or the Xact closed-cell stent.
Neurologic evaluation was performed using the Na-
tional Institutes of Health Stroke Scale by trained and
certified personnel before the procedure, before discharge,
and at the 30-day follow-up visit. All CAS procedures were
performed under monitored anesthesia care (local anesthe-
sia and intravenous sedation) through retrograde access
from the common femoral artery. All patients received dual
antiplatelet therapy with aspirin and a thienopyridine be-
fore the procedure and postoperatively. CAS procedures
were performed using a fixed angiographic unit (Allura
Xper FD20, Philips, Bothell, Wash). Procedural details and
CAS protocols at our institution followed techniques de-
scribed in detail before.19 To avoid variability in the degree
of subclinical cerebral embolization related to the type of
embolic protection used, all procedures were performed
with a single filter device (Accunet filter, Abbott Vascular).
Predilatation was selectively performed using rapid-
exchange balloons, 4 mm in diameter and 20 to 40 mm in
length. Postdilatation was also selectively performed using
monorail 5- or 5.5-mm balloons if residual stenosis after
stent placement was 20% to 30%. Completion angio-
grams, including cervical and cerebral views, were routinely
obtained. aBefore intervention and after embolic protection de-
ices deployment, VH-intravascular ultrasound (IVUS)
mages were obtained using a 2.9F, 20-MHz Eagle Eye
old catheter (Volcano Corp, Rancho Cordova, Calif)
ith an incorporated 20-MHz phased-array transducer be-
inning from the distal vessel, at least 10 mm distal to the
ulprit lesion and progressing in a retrograde direction to
he most distal common carotid artery free of disease.
irtual histology analysis was performed, as previously de-
cribed,20 in an automated fashion using Volcano S5 soft-
are (Volcano Corp).
All patients had DW-MRI scans of the brain obtained
mmediately before CAS and 18 to 24 hours after CAS.
W-MRI was obtained using standard head coils on 1.5-
esla Siemens scanners (Siemens Avanto or Magnetom
onata, Siemens, Erlangen, Germany). DW-MRI with
cho-planar imaging sequence (B0  1000) and fluid-
ttenuated inversion recovery images were obtained in axial
nd coronal sections. On the postprocedural MRI, acute
mbolic lesions were defined as focal hyperintense areas
ith restricted diffusion signal, which were confirmed by
pparent diffusion coefficient mapping to rule out artifacts.
ew postprocedural cerebral lesions consistent with micro-
mboli were recorded in terms of location and number for
ll DW-MRI examinations performed.
Bilateral transcranial Doppler scan monitoring of the
nterior and middle cerebral arteries was performed using a
MD150-ST3 digital transcranial Doppler pulsed-wave ul-
rasound scan system (Spencer Technologies, Seattle,
ash) with 2-MHz probes located over the temporal
ones above the zygomatic arch. Details of the TCD mon-
toring procedures are included in the Appendix (online
nly). The studies were stored on a hard drive and were
nalyzed off-line without the use of the automatic emboli
etection software. Isolated microembolic signals (MES)
ere identified from Doppler spectras according to the
riteria given by the Consensus Committee of the Ninth
nternational Cerebral Hemodynamic Symposium.21 If the
umber of MES was too high to be counted separately,
eartbeats with microemboli were counted as microem-
olic showers. To avoid confusion, MES detected during
ontrast injection were excluded from the analysis. For
nalysis purposes, the procedure was divided into the fol-
owing phases: lesion crossing,2 filter deployment,3 IVUS
xamination,4 predilation,5 stent deployment,6 postdilata-
ion (when applicable),7 and filter removal.
This clinical trial was designed as a randomized pro-
pective controlled trial designed to test the hypothesis that
he implantation of closed-cell stents for carotid lesions in
igh-risk patients was associated with a reduced periopera-
ive cerebral microembolization, as detected by TCD and
W-MRI, when compared with the implantation of open-
ell stents. The TCD and DW-MRI studies were assessed
y readers blinded to the clinical status, stent design, and
utcomes of the patients. Secondary endpoints included
echnical success, major or minor stroke, transient ischemic
ttacks, death, and stent thrombosis.
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November 20111312 Timaran et alSample size calculation was based on the MES counts
detected with TCD during CAS, as this was initially the
only primary endpoint of the trial. A total sample size of 34
patients was selected to provide a 90% statistical power at
the 0.01 level of significance to detect a 102MES count net
difference in response between groups (ie, open-cell vs
closed cell stents) with a SD of the differences estimated at
73. We randomized 40 participants (20 per group) to
account for a 20% dropout rate. This estimate of the
anticipated magnitude and variability of the response was
based on results reported by Rubartelli et al14 and Bosiers et
al.11 Such MES counts were based on the use of filter
embolic protection devices and closed-cell stents. A con-
servative twofold increased microembolization load as-
sociated with the use of open-cell stents was estimated
based on differences in neurologic adverse events re-
ported by Bosiers et al.11
Descriptive statistics for categorical variables are pre-
sented as relative frequencies and compared using 2 con-
tingency table analysis or Fisher exact test. Continuous
variables were expressed as medians and IQRs and com-
pared withMann–WhitneyU test. The association between
stent design (ie, open-cell vs closed-cell stents) and the
frequency of TCD-detected MES counts during CAS and
the incidence and location of acute postprocedural embolic
lesions detected withDW-MRIwere assessed with bivariate
statistical tests. Analyses were based on intention-to-treat.
Statistical significance was defined by a P value  .05. The
SAS 9.2 (SAS Institute, Cary, NC) and MedCalc http://
11.1.1.0 (MedCalc Software, Mariakerke, Belgium) soft-
ware programs were used for data analyses.
RESULTS
During an 18-month period, 40 patients were ran-
domly assigned to undergo CAS with either an open-cell or
a closed-cell stent. Demographic characteristics of the pa-
tients are shown in Table I. Dyslipidemia and hypertension
were significantly more frequent among patients in the
open-cell stent group than among those in the closed-cell
stent group (100% vs 70% for both comorbidities, respec-
tively; P  .02). There was also a trend for a higher
frequency of diabetes (65% vs 30%; P  .06) and chronic
renal insufficiency (25% vs 5%; P  .18) among patients
receiving open-cell stents. CAS was performed in 17 symp-
tomatic patients (43%) and 23 asymptomatic patients
(57%). The proportion of symptomatic patients was similar
in both arms of the study (9/20 [45%] in the open-cell
stent group and 8/20 [40%] in the closed-cell stent group;
P  .75). Indications for CAS included high surgical risk
due to severe comorbidities (42%), high lesion (lesion
above C2; 28%), contralateral carotid occlusion (20%), and
hostile neck (previous CEA, radical neck dissection, radia-
tion; 10%). No patients in this series had tandem lesions.
No significant differences among groups regarding the
indication for CAS and plaque composition based on VH-
IVUS were observed in this series (Tables I and II). Suc-
cessful revascularization (30% residual stenosis) was
achieved in all cases. One asymptomatic patient undergoing (AS with an open-cell stent sustained a minor stroke; the
0-day stroke-death rate in this series was 2.5%.
All patients underwent procedural TCD monitoring
ith interpretable results. Subclinical cerebral embolization
etected by TCDmonitoring was not significantly different
or CAS procedures performed with open-cell and closed-
ell stents. The total ipsilateral median MES counts de-
ected by TCDwere 264 (IQR, 222-343) during CAS with
pen-cell stents and 339 (IQR, 163-408) for CAS with
losed-cell stents, respectively (P  .56). The poststenting
psilateral median MES counts (ie, the MES that occurred
fter the stent was deployed and are, therefore, presumed to
e affected by stent design) were 48 (IQR, 41-66) and 58
IQR, 23-88) for open-cell and closed-cell stents, respec-
ively (P  .95). The contralateral median MES counts,
hich should not be affected by stent design, were 12
able I. Baseline characteristics of the study population
ccording to treatment group
haracteristic
Open-cell
stent
n  20
Closed-cell
stent
n  20
P
value
ge, years
Median 67.0 65 .71
Interquartile range 60.5-75.5 59.5-71.5
ale gender 100 100
hite race (% of patients) 95 100 1.0
ispanic ethnicity 20 10 .67
symptomatic arteries (% of
patients) 55 60 .75
isk factors (% of patients)
Hypertension 100 70 .02a
Diabetes 65 30 0.06b
Dyslipidemia 100 70 0.02a
Tobacco smoking 70 80 0.72
Treatment with statins 100 60 0.003a
Congestive heart failure 15 10 1.0
Coronary artery disease 45 45 1.0
Chronic obstructive pulmonary
disease 25 10 .41
Chronic renal insufficiency 25 5 .18
ercent stenosis at randomization
Moderate (70%) 40 50 .75
Severe (70%) 60 50 .75
natomic characteristics
Left carotid artery treated 60 50 .75
Contralateral occlusion 20 20 1.0
High carotid lesion (above C2) 25 30 1.0
Hostile neck (previous
endarterectomy, radical
neck dissection, radiation) 15 20 1.0
rocedural characteristics
Target lesion length (mm)
Median 20.5 23.5 .60
Interquartile range 16.5-24.8 16.4-29.0
Total length of stented
segment (mm) 40 40 .74
Balloon angioplasty before
stenting (% of patients) 90 80 .66
Fisher exact test.
The 2 contingency table analysis.IQR, 5-25) and 10 (IQR, 2-16) for open-cell and
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Volume 54, Number 5 Timaran et al 1313closed-cell stents, respectively (P  .48). The total me-
dian ipsilateral microembolic showers were 24 (IQR,
16-41) for open-cell stents and 28 (IQR, 15-45) for
closed-cell stents (P  .83).
After randomization, two patients with open-cell stents
and one patient with a closed-cell stent refused to undergo
postprocedural DW-MRI scans due to claustrophobia.
Among the 37 patients that completed postprocedural
DW-MRI examinations, three studies were considered un-
interpretable due to distortions by metal or severe motion
artifacts. New ischemic brain lesions detected with DW-
MRI occurred in 53% and 47% of patients undergoing CAS
with open-cell and closed-cell stents, respectively (P 1.0).
The total and ipsilateral median numbers of DW-MRI
lesions between groups were not statistically significantly
different (ie, 2 [IQR, 0-4] and 1 [IQR, 0-3] for open-cell
stents and 1 [IQR, 0-3] and 1 [IQR, 0-2] for closed-cell
stents [P  .4 and P  .7]), respectively. All patients with
positive DW-MRI after CAS were asymptomatic and re-
mained free of neurologic events at 30 days. Conversely,
one asymptomatic patient who underwent CAS with an
open-cell stent and whose postprocedural DW-MRI was
negative for new lesions had an ischemic hemispheric stroke
3 days after CAS. One patient that refused to have postpro-
cedural DW-MRI had a transient ischemic attack 19 days
after CAS with an open-cell stent.
DISCUSSION
The results of this randomized clinical trial indicate that
cerebral embolization, as detected by TCD and DW-MRI,
occurs with similar frequency after CAS with open-cell and
closed-cell stents. Our results did not support our hypoth-
Table II. Plaque composition based on virtual histology in
according to treatment groups
Characteristic
Plaque composition at minimum luminal area site (mm2)
Plaque burden
Fibrous
Fibrofatty
Dense calcium
Necrotic core
Plaque composition at largest necrotic core site (mm2)
Plaque burden
Fibrous
Fibrofatty
Dense calcium
Necrotic core
Plaque composition over entire lesion length (mm3)
Plaque burden
Fibrous
Fibrofatty
Dense calcium
Necrotic core
Data are expressed as median (interquartile range).
aIntravascular ultrasound scan was not performed in three patients of each g
bWilcoxon rank-sum test for independent samples.esis that closed-cell stents would reduce periprocedural derebral embolization compared with open-cell stents in
igh-risk patients with symptomatic and asymptomatic ex-
racranial carotid stenosis undergoing carotid stenting.
his trial, therefore, does not support the superiority of any
tent design with respect to cerebral embolization.
Strokes and transient ischemic attacks after CAS are
ortunately rare events, particularly when performed by
nterventionalists with large experience and in high-
olume centers.9 Cerebral embolization is still, however,
onsidered one of the main limitations of CAS. The use of
urrogate endpoints to assess the outcomes of carotid in-
erventions has been suggested to characterize cerebral
mbolization.16,18 Both TCD and DW-MRI have been
xtensively used to detect periprocedural subclinical brain
schemic injury after carotid interventions.14,16,22,23 The
linical significance of these microembolic lesions remains
ontroversial. In this study, both TCD and DW-MRI were
sed to obtain a thorough investigation of the degree of
ubclinical ischemic brain injury during and after CAS.
Because several neurologic events occur after removal
f the embolic protection device and completion of the
AS procedure, it is presumed that a high proportion of
tented carotid lesions continue to release embolic material
fter the carotid intervention.7,11 The recognition of em-
olization of plaque debris to the brain after CAS has
rompted the evaluation of different predictors of adverse
utcomes, including stent design and stent-free cell area.24
Stents have sequential aligned annular rings intercon-
ected by bridges. Depending on the density of the bridges
etween the different rings, nitinol stents can be classified
nto stents with a closed-cell or an open-cell configura-
ion.24 Flexibility and scaffolding are key characteristics
ascular ultrasound scan findings before carotid stenting
pen-cell stent
(n  17)a
Closed-cell stent
(n  17)a P valueb
9 (78.2-86.8) 85.6 (84.4-87.5) .08
8 (11.0-16.2) 17.6 (11.4-17.6) .37
7 (2.6-6.4) 5.6 (3.5-8.1) .45
7 (0.4-1.1) 0.4 (0.2-1.7) .77
8 (1.5-5.0) 2.7 (1.5-4.0) .65
6 (66.7-78.2) 73.7 (63.2-82.4) .89
7 (8.8-15.0) 12.9 (8.5-15.8) .59
1 (1.2-3.7) 2.2 (1.5-3.3) .98
1 (0.5-1.9) 1.0 (0.5-3.3) .56
0 (3.5-6.7) 5.7 (3.6-6.3) .63
9 (159.2-517.8) 273.9 (165.3-408.8) .81
5 (78.0-254.1) 110.0 (72.8-186.6) .74
2 (23.3-68.2) 19.1 (12.2-56.7) .24
4 (7.8-20.3) 10.3 (7.1-30.7) .99
0 (22.8-106.2) 33.4 (27.5-50.3) .60trav
O
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November 20111314 Timaran et alability to conform to vessel tortuosity in the deployed state.
Closed-cell stents are rigid, less flexible, and may be prone
to kinking or incomplete deployment in tortuous vessels.
Conversely, stents with an open-cell configuration conform
best to tortuous anatomy. Scaffolding refers to the amount
of support given to the vessel wall by a stent. Insufficient
scaffolding could hypothetically lead to distal embolization
from a vulnerable plaque and clinical stroke if plaque ma-
terial is extruded through the struts of the stent. In theory,
an open-cell structure would increase the risk of plaque
material extruding through the interstices of the stent
during deployment, postdilatation, and after the CAS pro-
cedure. Closed-cell stents could potentially offer maximal
scaffolding to the carotid lesion and potentially lower the
risk of plaque extrusion and embolization.
In most CAS procedures, either open-cell or closed-cell
stents may be used. The choice of the optimal carotid stent
is frequently based on arterial anatomy and, to a lesser
extent, lesion morphology. When treating a tortuous ves-
sel, stents with a flexible and conformable open-cell config-
uration may be preferable. Lesions with suspected high
embolic potential could be primarily treated with stents
with a closed-cell configuration if cerebral embolization
could be prevented. To date, optimal clinical evaluation of
carotid plaque vulnerability and embolic potential have
been limited. In fact, we reported in a recent observational
study that plaque composition, as determined by VH-
IVUS, only weakly correlated with the degree of cerebral
embolization after carotid stenting.20 Moreover, the pro-
portion of necrotic core, which has traditionally been con-
sidered the main component of a vulnerable or unstable
plaque, was not definitely associated with subclinical cere-
bral embolization after CASwhen a filter device for embolic
protection was used. The use of closed-cell stents during
CAS to prevent cerebral embolization, including those
instances in which VH-IVUS suggests increased vulnerabil-
ity based on plaque composition, is not supported by the
results of this clinical trial and our prior observational
study.20
Two recent observational studies from the same au-
thors suggest that stents with closed-cell design result in a
significant decrease in periprocedural neurologic events
after CAS.10,11 In an initial retrospective study, including
701 consecutive CAS procedures performed at two centers,
CAS procedures performed with closed-cell stents were
associated with a clear reduction of neurologic events com-
pared with open-cell stents (3.4% vs 1.3%, respectively).10
Open-cell stent designs were, in fact, associated with a
fourfold increased risk of 30-day stroke/death/transient
ischemic attack (odds ratio, 4.1; 95% confidence interval,
1.4-12; P  .0136). In a subsequent retrospective obser-
vational multicentric study,11 the authors expanded their
initial series and included patients that underwent 3179
consecutive CAS procedures. The influence of stent types
and designs on the distribution of adverse neurologic
events after CAS was assessed in terms of specific stents
used, free cell areas (0-2.5 mm2, 2.5-5 mm2, 5-7.5 mm2,
and 7.5 mm2) and cell design (open-cell vs closed-cell ftents). The overall combined rate of transient ischemic
ttack, stroke, and death was 2.8% at 30 days (late events
.9%). The late event rates varied from 1.2% to 3.4% for free
ell areas2.5mm2 and7.5mm2, respectively (P .05).
ostprocedural event rate was 1.3% for closed-cell stents
nd 3.4% for open-cell stents. All these differences were
rimarily identified among symptomatic patients (P 
0001). The authors concluded that after CAS, postproce-
ural neurologic adverse events are significantly influenced
y stent type, free cell area, and cell design. In the symp-
omatic population (and also in the total population),
ostprocedural complication rates were highest for the
pen-cell types and increased with larger free cell areas.
Although these two observational studies suggest in-
reased risk of embolization with the use of open-cell
tents, no significant differences in major adverse events,
ncluding stroke and death rates, have been reported in a
arge number of registries and postmarketing studies of
arotid stents efficacy among different stent designs.25-27
irect comparisons of open-cell vs closed-cell stents has,
owever, rarely been performed. Prospective randomized
linical trials comparing different free cell areas and stent
esigns are still needed to further investigate their influence
n CAS outcomes. Because a true superiority in the efficacy
f closed-cell stents in preventing cerebral embolization
nd adverse neurologic events has not been demonstrated,
e strongly caution against adopting their widespread use
n all CAS procedures as kinks and incomplete deployment
ay occur more frequently with these more rigid stents.
Although this is a randomized clinical trial of open-cell
s closed-cell stents with objective evaluation of cerebral
mbolization using TCD monitoring during CAS and
W-MRI examinations obtained before and after CAS,
mportant limitations should be acknowledged. First of all,
ur study includes a small sample size and the primary
ndpoint only focused on periprocedural subclinical cere-
ral embolization; thus, the results should be considered
reliminary, as differences in neurologic events could not
e assessed statistically between groups. Moreover, this was
ot designed as an equivalency trial and, therefore, the
esults should not be interpreted as evidence that the two
reatments are equivalent. Second, randomization did not
liminate all pretreatment differences between groups be-
ause of the small sample size. For instance, dyslipidemia,
ypertension, diabetes, treatment with statins, and chronic
enal insufficiency were more frequent in patients undergo-
ng CAS with open-cell stents compared to those receiving
losed-cell stents. Although a multivariate analysis would
e desirable to determine if stent design had an impact on
erebral embolization after adjusting for the effects of other
ovariates, this was not feasible given the small sample size
nd limited number of positive events. Third, all patients in
ur study underwent CAS under filter embolic protection,
hich could have limited the role of stent design in influ-
ncing distal embolization during CAS, particularly in
hose instances in which embolic protection is not used.
ecause CAS without embolic protection is rarely per-
ormed due to ethical and regulatory considerations, our
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results indicate that carotid plaque composition can only
weakly predict distal embolization, and even if we could
accurately predict lesions most likely to embolize, it is
unclear if distal subclinical embolization may be prevented
by one type of stent design and, if so, does that translate
into better clinical outcomes? Randomization, however,
resulted in comparable groups in terms of symptomatic
status and plaque composition, according to VH-IVUS.
Adjusting the effects of stent design on cerebral emboliza-
tion according to symptomatic status and plaque composi-
tion was, therefore, unnecessary. Fifth, the applicability of
the results of this trial to standard-risk patients is not
definitive, as the results of CAS may vary according to
medical and anatomic risk. Finally, albeit frequently used,
only one type of open-cell and closed-cell stents was eval-
uated in this trial. Further investigations are therefore nec-
essary regarding the effects of stent-free cell area and other
types of stents on cerebral embolization, particularly those
under development that include absorbable, helical, hy-
brid, multilayer and covered stents, and those constructed
with a high-density mesh. The clinical significance of sub-
clinical cerebral embolization after CAS, the effectiveness
of distal protection devices in preventing embolization, and
the ultimate impact of reducing distal embolization on the
frequency of stroke remain uncertain and warrant further
investigation.
In conclusion, cerebral embolization, as detected by
TCD and DW-MRI, occurs with similar frequency after
CASwith open-cell and closed-cell stents. This randomized
trial does not support the superiority of any stent design
with respect to subclinical cerebral embolization. We cau-
tion, therefore, against using preferentially closed-cell
stents in all CAS procedures as kinks and incomplete de-
ployment may occur more frequently with these more rigid
stents.
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Dr Charles B. Ross (Louisville, KY). I would like to congrat-
ulate Dr Timaran and his colleagues from the University of Texas,
Southwestern for an excellent paper which represents another mile-
stone in their efforts to differentiate patient, device, and technical
factors which might have utility in helping us to more safely imple-
ment carotid artery stenting. The question posed in the present study
relates to open vs closed-cell stent design and whether this influences
intra-procedural cerebral embolization as a surrogate for adverse
neurological outcomes. And, you showed no differences in either
intra-procedural TCD microembolic signals or early DW-MRI
changes between the two stent designs.
Yet, one-third ormore adverse neurologic events occur 24 hours
to 30 days following completion of CAS. In the present study, you
report the occurrence of a stroke 3 days postprocedure in an asymp-
tomatic patient in the open cell group and one transient ischemic
attack in a an open-cell patient at 19 days postprocedure. My first
observation is that your study designwith use of intra-proceduralTCD
and early 18 to 24 hour postprocedural MRI as surrogates for adverse
neurologic outcomemay not precisely address the clinical question as to
the ultimate potential superiority of one stent design over the other.
Can you review for us the specific information as to the plaque
morphology in the two patients who had adverse neurologic events as
well as any additional insight as to what happened in those cases? Are
you completely comfortable that intra-procedural embolization as a
surrogates for adverse neurologic events adequately addresses the clinical
question as to the ultimate benefit of closed cell versus open cell stents?
When I look at the issue of closed-cell vs open-cell stents forCAS,
I must reflect on the Belgium- Italian Carotid (BIC) Registry1 in
which this issue of superiority of closed-cell stents was initially raised.
In that registry, the difference between designs was primarily seen in
symptomatic patients and much emphasis was made on the particu-
larly protective benefit of closed-cell stents in terms of reduction
postprocedure events. In the study reported by Schillinger, at al,2
there was a nonsignificant trend towards fewer “subacute” events in
patients who hadCASwith closed-cell stents. The studymay not have
been adequately powered to demonstrate an effect. The MRIs were
performed early in your study. Did you consider delaying theMRI to
better reflect postprocedure events?
In the BIC registry, the vast majority of closed-cell stents were
carotid Wallstents. Why did you use only the EXACT stent? Did you
consider use of the carotid Wallstent? Do you think it would have
made a difference?
Third, we continue to seek refinements in carotid artery tech-
nique based on preprocedural patient, anatomic, and plaque char-
acteristics. However, your findings last year on plaque morphol-
ogy3 and now this year on stent design have not confirmed
conventional wisdom from observational studies and have failed to
provide positive technical guidance.
So, I ask you now, do you use the same system for every patient?I greatly appreciate receipt this manuscript with plenty of time
o review, and I thank the society for the privilege of the floor to
pen this discussion.
DrCarlosH. Timaran.Thank you,Charles, for your questions
nd comments. First, yes, there were two events: one TIA that
appened almost 19 days after the procedure and then aminor stroke
hat happened 3 days after the procedure. Of note, none of those
atients actually have a positive MRI for cerebral embolization, but
ne could argue that a lateMRIwould have revealedmicroemboli. As
ar as the plaque composition of those two patients, it was not
articularly relevant. Both had about 10% proportion of necrotic core
ut there were no other relevant plaque composition features.
You asked me what I think about using TCD and MRI as
urrogates for adverse neurologic events. I have to say that after the
REST trial, we have two procedures, stenting and endarterectomy,
hich are really good and have a really low number of positive
utcome events in terms of strokes and deaths. To avoid designing
arge and expensive trials, it has been suggested that surrogate end
oints should be used, and in fact, the ICSS substudy used cerebral
mbolization detectedwithDW-MRI as a surrogate end point, which
roved to be actually a very good one and helped to solve some bias
ssues applicable to the whole cohort of patients.
Why did we choose Xact stents? It was primarily because it was
he only one available. As you know the carotid Wallstent was ap-
roved later. When we designed this study and submitted our grant
roposal the only closed-cell stent we had available was the Xact stent.
ow, yes, I agree that this study in a way contradicts what is being
hown by other observational studies, but the importance of doing
andomized clinical trials is that you compare directly two different
reatment groups without the bias of patient or case selection.
Howdo I choose a stent?Well, I have to say that at this pointwith
he stents we have, I don’t think stent design is that important. I focus
ore on the type of embolic protection based on symptomatic status.
also focusmore on anatomy. I always try to get CTAs, particularly in
ctogenarians that I am considering for stenting. I think in the future
s absorbable stents or those stents constructed with high-density
eshes or cover stents become available, wewill actually use stent design
s a way to improve the results of carotid stenting.
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For transcranial Doppler monitoring, the probes were
secured to the patient’s head using a commercially available
probe-holding head frame system (Marc 600 series; Spen-
cer Technologies, Seattle, Wash). Doppler parameters were
as follows: pulse repetition frequency, 8 kHz; fast Fourier
transformation, 128 points; overlap, 66%; sample volume
axial length, 9 mm; output power, 80% to 100%; filter, 125
to 175 Hz; noise, 0-3 dB; range, 30 dB; Doppler volume,
4 dB; M-mode range, 30 dB; and sweep period, 4 to 16 reconds. Monitoring was started at the time of femoral
uncture and continued for at least 10 minutes after re-
oval of the embolic protection device. Timing of all the
teps of the stenting procedure, including advancement of
he guides and catheters into the aortic arch and internal
arotid artery, crossing the carotid lesion with the different
evices, deployment of embolic protection device and
tent, balloon inflation, IVUS examination, filter retrieval,
nd all the injections of contrast were recorded in case
eport forms.
